SRTS

Sensus Healthcare, Inc. (SRTS) - 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Sensus Healthcare, Inc. is a medical device company manufacturing radiation therapy devices (SRT-100 series) for treating skin conditions. The company operates globally with a single reportable segment and recently launched a "Fair Deal Agreement" service model through its subsidiary, Sensus Healthcare Services, LLC, to provide operational healthcare services to dermatology clinics.

Key Financial Metrics

Note: The company has no outstanding borrowings under its new revolving credit facility as of June 30, 2026.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 68.5% quarter-over-quarter (QoQ) and 63.7% year-over-year (YoY) for the six-month period. This was primarily driven by a significant drop in unit sales (6 units in Q2 2026 vs. 19 in Q2 2025) and the absence of sales to a historically large customer that accounted for 56% of revenue in the prior year's quarter.
• Margin Compression: Gross margin declined to 33.6% (Q2 2026) from 39.7% (Q2 2025). This was attributed to a product mix shift toward international shipments with lower average selling prices and upfront costs associated with new "Fair Deal Agreement" placements where revenue is recognized over time.
• Inventory Build: Inventories increased by $3.9 million to $18.5 million, reflecting anticipation of future sales despite current revenue headwinds.
• Income Tax Expense: The company recorded a significant income tax expense of $5.7 million for the quarter (vs. a benefit of $0.7 million in the prior year) due to a full valuation allowance against net deferred tax assets, driven by recent operating losses.

Guidance, Outlook, and Risks

• Liquidity: Management believes existing cash reserves ($15.2 million) and maturing cash equivalents are sufficient to meet operating requirements for the next 12 months. No borrowings were outstanding under the new $15 million credit facility with City National Bank of Florida (CNB) as of the reporting date.
• Debt Facility: The company terminated a prior facility with Fifth Third Bank due to covenant defaults and secured a new facility with CNB in June 2026. The new facility requires $2.2 million in restricted cash as collateral. A minimum debt service coverage ratio of 1.50 will apply only if the remaining $13 million commitment is made available.
• Legal Contingencies: The company is under investigation by the Department of Justice regarding billing practices by a physician using its devices. The company disputes any wrongdoing and has not estimated a potential cost.
• Geopolitical Risks: The company monitors geopolitical tensions between the U.S. and China, noting that while there has been no significant impact to date, future developments could affect operations.

Investor Verification Checklist

• Customer Concentration: Verify the status of the historically large U.S. customer that drove 56% of revenue in Q2 2025 but contributed zero revenue in Q2 2026.
• Valuation Allowance: Assess the sustainability of the full valuation allowance against deferred tax assets and the likelihood of reversal in future profitable periods.
• Inventory Levels: Monitor the $18.5 million inventory balance against future sales execution to ensure no impairment charges are required.
• DOJ Investigation: Track updates on the Department of Justice investigation regarding Medicare billing codes.
• Credit Facility Covenants: Confirm whether the company will trigger the financial covenants (1.50 debt service coverage) if the full $15 million credit line is utilized.